Invuity, Inc. – Trademark Portfolio
Entity Type: 03
Invuity, Inc. holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 22 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include EIKON, EIBERG, INVUITY, HIDDEN SCAR, and PHOTONBLADE. The owner is based in San Francisco, CA.
39 Stillman Street
San Francisco, CA 94107
Showing of trademarks Trademarks
Trademark Classifications
Invuity, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does Invuity, Inc. have?
Invuity, Inc. has 26 U.S. trademarks filed with the USPTO. Of these, 8 registered, 12 abandoned, 6 cancelled.
What trademark classes does Invuity, Inc. file in?
Invuity, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Invuity, Inc.'s most well-known trademarks?
Invuity, Inc.'s registered trademark portfolio includes well-known marks such as EIKON, EIBERG, INVUITY, HIDDEN SCAR, and PHOTONBLADE. These are among 8 currently registered trademarks in the portfolio.
What is Invuity, Inc.'s trademark registration success rate?
Invuity, Inc. has a 31% trademark registration rate, with 8 out of 26 resolved applications resulting in successful registration. Currently, 0 applications are pending review.